Lee Y J, Daida H, Yokoi H, Miyano H, Takaya J, Sakurai H, Mokuno H, Yamaguchi H
Department of Cardiology, Juntendo University, School of Medicine, Tokyo, Japan.
Jpn Heart J. 1996 May;37(3):327-32. doi: 10.1536/ihj.37.327.
Lipid lowering therapies were employed to prevent restenosis following elective percutaneous transluminal coronary angioplasty (PTCA). The effect of probucol was compared to that of Pravastatin in 141 coronary atherosclerosis patients. Probucol (750 mg/day) was administered for at least 30 days prior to PTCA (34 patients, group P-1) or less than 14 days prior to PTCA (27 patients, group P-2). Pravastatin (10 mg/day) was administered for at least 30 days prior to PTCA (38 patients, group V-1) or less than 14 days prior to PTCA (42 patients, group V-2). In group P-1, the patient restenosis rate was 17.6% and lesion restenosis rate was 14%. These rates were significantly lower than those of group V-1, which were 44.7% and 40.4% respectively (p < 0.05). The respective values were 48.1% and 51.8% in group P-2 (p < 0.05, vs group P-1) and 35.7% and 34% (p < 0.05, vs group P-1) in group V-2. Probucol seems to work, not only by lowering cholesterol but also by its antioxidative properties when administered for a sufficient period prior to PTCA.
采用降脂疗法预防择期经皮腔内冠状动脉成形术（PTCA）后的再狭窄。在141例冠状动脉粥样硬化患者中比较了普罗布考与普伐他汀的效果。普罗布考（750毫克/天）在PTCA前至少服用30天（34例患者，P - 1组）或在PTCA前少于14天服用（27例患者，P - 2组）。普伐他汀（10毫克/天）在PTCA前至少服用30天（38例患者，V - 1组）或在PTCA前少于14天服用（42例患者，V - 2组）。在P - 1组中，患者再狭窄率为17.6%，病变再狭窄率为14%。这些比率显著低于V - 1组，V - 1组的比率分别为44.7%和40.4%（p < 0.05）。P - 2组的相应值分别为48.1%和51.8%（p < 0.05，与P - 1组相比），V - 2组为35.7%和34%（p < 0.05，与P - 1组相比）。普罗布考似乎不仅通过降低胆固醇起作用，而且在PTCA前足够长的时间给药时还通过其抗氧化特性起作用。
